| Excerpt | Reference |
|---|
| "Hairy cell leukemia is a malignant B-cell disorder characterized by splenomegaly and pancytopenia." | ( Husney, RM; Kraut, EH; Sagone, AL, 1992) |
| "Hairy cell leukemia is a chronic lymphoproliferative disorder of B-cell lineage, whose malignant cells express the interleukin-2 (IL-2) receptor." | ( Daly, K; Golomb, HM; Latta, JM; Mick, R; Ratain, MJ; Richards, JM; Vardiman, JW, 1990) |
| "Hairy cell leukemia is a chronic disorder caused by expansion of a clonal population of an unusual mononuclear cell of B cell origin." | ( Clark, J; Longo, DL; Maluish, AE; Marcon, L; Nelson, DL; Steis, RG; Urba, W, 1988) |
| "An unusual case of hairy cell leukemia is reported." | ( Arkel, YS; Berman, E; Lake-Lewin, D; Savopoulos, AA, 1984) |
| "Hairy cell leukemia is a malignancy with a variable course that can be relatively indolent or rapidly fatal." | ( Golomb, HM; Offermann, MK, 1984) |
| "A father and son hairy cell leukemia are identified on the basis of tartrate-resistant acid-phosphatase-positive hairy cells and diagnostic bone core biopsies." | ( Collins, JL; Golomb, HM; Oleske, D; Ramseur, WL; Vardiman, JW, 1981) |
| "Hairy cell leukemia is an uncommon B cell lymphoproliferative disease of unknown etiology." | ( Ahn, NG; Clark, EA; Genot, EM; Licciardi, KA; Meier, KE; Uittenbogaart, CH; Valentine, MA; Wietzerbin, J, 1993) |
| "Hairy cell leukemia is a rare chronic B-lymphocyte malignancy characterized by pancytopenia, splenomegaly, immunological abnormalities and morphologically typical neoplastic mononuclear cells in blood and bone marrow." | ( Evensen, SA; Heldal, D; Juliusson, G; Tjønnfjord, GE, 1994) |
| "Hairy cell leukemia is a rare lymphoproliferative B disorder." | ( Guerci, A; Lederlin, P; Paitel, JF, 1996) |
| "Hairy cell leukemia is a rare chronic lymphoproliferative disorder originating probably in a pluripotent stem cell." | ( Arruda, VR; Costa, FF; Saad, ST; Salles, TS, 1996) |
| "Hairy cell leukemia is a chronic lymphoproliferative disorder of B-cell lineage." | ( Chrobák, L; Kerekes, Z; Palicka, V; Plísková, L; Podzimek, K; Spacek, J; Voglová, J; Zák, P, 1996) |
| "Hairy cell leukemia is notably responsive to 2-CdA, with 85% of patients entering complete remissions after treatment of this drug." | ( Góra-Tybor, J; Robak, T, 1996) |
| "Hairy cell leukemia is a chronic B-cell disorder that follows an indolent, but progressive course." | ( Burian, C; Koziol, JA; Piro, LD; Saven, A, 1998) |
| "Active hairy cell leukemia is associated with an increase of RDW (Red Cell Distribution Width) which normalizes after successful therapy with 2-chlorodeoxyadenosine (2-CdA)." | ( Chrobák, L; Dedic, K; Plísková, L; Podzimek, K; Zák, P, 1998) |
| "Hairy cell leukemia is a rare lymphoproliferative disorder resistant to conventional chemotherapeutic agents." | ( Chott, A; Füreder, W; Geissler, K; Gisslinger, H; Jäger, U; Lechner, K; Valent, P; Weltermann, A, 1999) |
| "Hairy cell leukemia is an uncommon chronic B cell lymphoproliferative disorder in Taiwan and only sporadic cases have been noted." | ( Ho, CH; Yang, MH, 2001) |
| "Hairy cell leukemia is an uncommon B-cell lymphoproliferative disease of unknown etiology in which tumor cells display characteristic microfilamentous membrane projections." | ( Anies, G; Basoni, C; Chaigne-Delalande, B; Deuve, L; Garand, R; Génot, E; Kramer, I; Lafarge, D; Reuzeau, E; Tatin, F; Varon, C, 2006) |
| "Hairy cell leukemia is a rare, indolent, chronic lymphoproliferative disorder characterized by the proliferation of a malignant B-cell clone with irregular cytoplasmic projections." | ( Gidron, A; Tallman, MS, 2006) |
| "Hairy cell leukemia is often reported as a disease of young males." | ( Juliusson, G; Samuelsson, H, 2011) |
| "Hairy cell leukemia is a mature B-cell non-Hogkin lymphoma characterized by unique clinical, morphological and immunhistochemical features." | ( Demeter, J; Nagy, Z; Sári, E, 2013) |
| "Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection." | ( Abdel-Wahab, O; Andritsos, LA; Banerji, V; Barrientos, J; Blachly, JS; Call, TG; Catovsky, D; Dearden, C; Demeter, J; Else, M; Falini, B; Forconi, F; Gozzetti, A; Grever, MR; Ho, AD; Johnston, JB; Jones, J; Juliusson, G; Kraut, E; Kreitman, RJ; Larratt, L; Lauria, F; Lozanski, G; Montserrat, E; Parikh, SA; Park, JH; Polliack, A; Quest, GR; Rai, KR; Ravandi, F; Robak, T; Saven, A; Seymour, JF; Tadmor, T; Tallman, MS; Tam, C; Tiacci, E; Troussard, X; Zent, CS; Zenz, T; Zinzani, PL, 2017) |
| "Hairy cell leukemia is an uncommon chronic B-cell lymphoproliferative disorder." | ( Andrasiak, I; Rybka, J; Wrobel, T, 2018) |
| "Hairy cell leukemia is a rare hematologic malignancy characterized by splenomegaly, pancytopenia, and susceptibility to infections." | ( Doma, A; Škerget, M; Žagar, I, 2019) |
| "Hairy cell leukemia is rare, and the diagnosis and differential diagnosis should be made by combining the patient's medical history, clinical manifestations, immunophenotype, gene detection, and other means." | ( Cui, HH; Jin, LF; Shen, WZ; Zhao, HL; Zhao, M, 2021) |
| Excerpt | Reference |
|---|
| "Two patients with hairy cell leukemia treated with the anthracycline antibiotic rubidazone are presented." | ( Benjamin, RS; Keating, M; McCredie, KB; Murphy, S; Stewart, DJ, 1979) |
| "Eleven patients with hairy cell leukemia (HCL) were treated with YK-176 (2'-deoxycoformycin) at a dose of 5 mg/m2 by intravenous injection every week or every other week." | ( Hirashima, K; Hotta, T; Itoh, S; Konishi, H; Mikuni, C; Shimoyama, M; Tobinai, K; Togawa, A; Toyoda, N; Yamaguchi, K, 1992) |
| "Sixteen patients with symptomatic hairy cell leukemia were treated with a single course of 2-chloro-2'-deoxyadenosine (CdA), 0." | ( Juliusson, G; Liliemark, J, 1992) |
| "The treatment of hairy cell leukemia (HCL) requires continuing update." | ( Daly, K; Golomb, HM; Mick, R; Ratain, MJ, 1992) |
| "Twenty-six patients with hairy cell leukemia (HCL) were treated with 2-chlorodeoxyadenosine (2-CdA), a purine analogue resistant to adenosine deaminase, at 0." | ( Hakimian, D; Kaul, K; Koslow, D; Rademaker, AW; Rose, E; Sisney, GA; Tallman, MS; Variakojis, D, 1992) |
| "In ten patients with hairy cell leukemia (HCL) and seven patients with other B-cell chronic leukemias (BCL), we have studied the intracellular 2',5'-oligoadenylate synthetase (2,5OAS) activity of the mononuclear cells before, 4 h, 24 h, and 48 h after pentostatin administration." | ( Dietz, G; Gross, A; Ho, AD; Hunstein, W; Jakobsen, H; Klotzbücher, A; Mestan, J, 1992) |
| "Although highly active in hairy cell leukemia (HCL), interferons (IFN) are not curative in this disease; current data indicate that prolonged IFN therapy will be necessary to control disease in the majority of patients." | ( Barney, R; Evans, LM; Ewel, CH; Itri, LM; Longo, DL; Smith, JW; Steis, RG; Urba, WJ; Venzon, DJ, 1991) |
| "Fifty patients with hairy cell leukemia were treated with pentostatin (2'-deoxycoformycin; dCF) for a median of 3 months; 32 (64%) patients achieved complete remission (CR), and 10 (20%) patients achieved partial remission (PR), for an overall response rate of 84%." | ( Bennett, JM; Cassileth, PA; Cheuvart, B; Cummings, FJ; Harrington, DP; Neiman, RS; O'Connell, MJ; Spiers, AS, 1991) |
| "Two patients with hairy cell leukemia (HCL) who failed alpha-2a-interferon and one who failed beta-ser-interferon were treated with 2'-deoxycoformycin (DCF), 4 mg/m2, by intravenous bolus infusion every 2 weeks." | ( Dutcher, JP; Salva, KM; Wiernik, PH, 1990) |
| "Fifteen patients with hairy cell leukemia (HCL) were treated with deoxycoformycin (pentostatin; dCF) (4 mg/m2 intravenous [IV] every week x 3) and recombinant interferon-alpha 2a (rIFN-alpha 2a) (3 x 10(6) units subcutaneously [SC] daily x 4 weeks) in alternating months for a total of 14 months." | ( Clark, JW; Creekmore, SP; Hawkins, MJ; Lawrence, JB; Longo, DL; Martin, A; Nerenstone, S; Smith, JW; Steis, RG; Urba, WJ, 1990) |
| "The immune function of patients with hairy cell leukemia (HCL) and solid tumors was evaluated before and after treatment with the investigational drug 2'-deoxycoformycin (pentostatin; dCF)." | ( Bouroncle, BA; Gochnour, D; Grever, MR; Kraut, EH; Neff, JC, 1990) |
| "This work considers the new advances in hairy cell leukemia therapy." | ( Boccaccio, P; Casciaro, S; Gatti, AM; Ghio, R; Rosa, F, 1989) |
| "Twenty-two patients with hairy cell leukemia were treated with low-dose interferon alfa-2b (0." | ( Daly, KM; Golomb, HM; Moormeier, JA; Ratain, MJ; Vardiman, JW; Westbrook, CA, 1989) |
| "Immune function in patients with hairy cell leukemia (HCL) was examined serially during treatment with alternating monthly cycles of recombinant interferon alpha-2a and 2'-deoxycoformycin (dCF)." | ( Baseler, MW; Clark, JW; Coggin, DL; Kopp, WC; Longo, DL; Smith, JW; Steis, RG; Urba, WJ, 1989) |
| "A patient with hairy cell leukemia (HCL) and vasculitis was treated only with interferon alpha-2b." | ( Garcia-Guajardo, BM; Garcia-Taboada, BE; Gómez-Almaguer, D; Herrera-Garza, JL, 1989) |
| "Recent studies have shown that hairy cell leukemia (HCL) may respond to treatment with the ADA inhibitor, 2-deoxycoformycin." | ( Dietz, G; Ho, AD; Hoffbrand, AV; Hunstein, W; Schwartz, R; Trede, I, 1986) |
| "A 73-year-old patient with hairy cell leukemia and profound granulocytopenia both before and after splenectomy was treated with lithium carbonate." | ( Levine, MA; Toback, AC, 1987) |
| "A patient with advanced hairy cell leukemia initially had a short-lived minor response to interferon alpha therapy and failed to respond to interferon gamma." | ( Golomb, HM; Lembersky, BC; Ratain, MJ; Westbrook, C, 1988) |
| "The sera of 26 patients with hairy cell leukemia were examined for the presence of a soluble IL-2 receptor before and during therapy with either recombinant interferon alpha-2a or 2'-deoxycoformycin." | ( Clark, J; Longo, DL; Maluish, AE; Marcon, L; Nelson, DL; Steis, RG; Urba, W, 1988) |
| "Using two examples, hairy Cell leukemia (HCL) and renal cell cancer (RCC), it is shown that the requirements for successful IFN-alpha therapy of HCL and RCC are different." | ( Digel, W; Heimpel, H; Jacobsen, H; Kirchner, H; Mittnacht, S; Porzsolt, F, 1988) |
| "Two patients with hairy cell leukemia with massive splenomegaly and severe pancytopenia were treated with recombinant alpha-A interferon (IFN-alpha-2a)." | ( Foon, KA; Koller, CA; Longo, DL; Nakano, GM; Steis, RG, 1986) |
| "Ten patients with progressive hairy cell leukemia were treated with 2'deoxycoformycin (dCF) by intravenous bolus (4 mg/m2) given every other week." | ( Bouroncle, BA; Grever, MR; Kraut, EH, 1986) |
| "Three patients with advanced hairy cell leukemia received low-dose deoxycoformycin treatment after failure to respond to therapy with interferon alpha." | ( Ho, AD; Hunstein, W; Kuse, R; Porzsolt, F; Prümmer, O, 1987) |
| "Six patients with relapsed hairy cell leukemia after splenectomy were treated with high-dose methotrexate and leucovorin rescue." | ( Hagenbeek, A; Joosten, P; Löwenberg, B; Sizoo, W, 1985) |
| "Treatment strategies for hairy cell leukemia have evolved and are being modified as more is learned about the disease." | ( Golomb, HM; Offermann, MK, 1984) |
| "Human hairy cell leukemia (HCL) cells in culture showed a marked increase in both [1-14C]acetate and [14C]choline incorporation into phosphatidylcholine (PC) when treated with a 10 nM concentration of 12-O-tetradecanoylphorbol 13-acetate (TPA) for 3 h." | ( Dawson, G; Golomb, HM; Lockney, MW, 1984) |
| "A splenectomized patient with hairy cell leukemia (HCL) who had received chemotherapy with a low-dose alkylating agent for 2 years developed dysmyelopoietic syndrome (DMPS), the first such case to be described." | ( Albain, KS; Golomb, HM; Le Beau, MM; Rowley, JD; Vardiman, JW, 1983) |
| "Two patients with progressive hairy cell leukemia following splenectomy were treated with low-dose daily chlorambucil." | ( Krigel, R; Liebes, LF; Pelle, E; Silber, R, 1982) |
| "Of eight patients with progressive hairy cell leukemia who were treated with daily doses of an alkylating agent (chlorambucil, 4 mg) for at least 6 mo, seven have had an objective response, as measured by improved blood counts." | ( Golomb, HM, 1981) |
| "Six patients with hairy cell leukemia have been treated with 2-chloro-2'-deoxyadenosine in a dose 0." | ( Błasińska-Morawiec, M; Krykowski, E; Robak, T; Urbańska-Ryś, H, 1994) |
| "A preliminary study of six hairy cell leukemia patients treated with one course of 2-chloro-2'-deoxyadenosine (2-CdA) is presented." | ( Hansz, J; Kaźmierczak, M; Komarnicki, M, 1994) |
| "Therapy of hairy cell leukemia has markedly improved." | ( Bennett, JM; Cassileth, PA; Corbett, WE; Foucar, MK; Golomb, H; Grever, M; Habermann, T; Head, D; Hutchison, RE; Kopecky, K, 1995) |
| "Eighty-five hairy cell leukemia (HCL) patients who had failed initial therapy with recombinant alpha interferon were enrolled for pentostatin therapy." | ( Budman, D; Dodge, R; Golomb, HM; Horning, SJ; Hutchison, R; Mick, R; Schiffer, CA, 1994) |
| "Thirty seven hairy cell leukemia (HCL) patients, 35 males and 2 females with a median age of 53 years, were treated with a single course of 2-Chlorodeoxyadenosine (2-CdA) at a dose of 0." | ( Benfenati, D; Benni, M; Lauria, F; Pileri, S; Poggi, S; Raspadori, D; Rondelli, D; Sabattini, E; Tura, S; Ventura, MA, 1994) |
| "More than 450 patients with hairy cell leukemia have been treated at the Scripps Clinic." | ( Piro, LD; Saven, A, 1993) |
| "Twenty-four patients with advanced hairy cell leukemia treated with 2'-deoxycoformycin (dCF) were studied after achieving complete remission to determine the impact of treatment on survival, disease-free survival, long-term complications of treatment, and response to retreatment." | ( Bouroncle, BA; Grever, MR; Kraut, EH, 1994) |
| "Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA) induces complete remissions in 85% of patients." | ( Ellison, DJ; Leopard, JD; Piro, LD; Robbins, BA; Saven, A; Sharpe, RW; Spinosa, JC, 1994) |
| "Five patients with hairy cell leukemia who had been previously treated with DCF." | ( Piro, LD; Saven, A, 1993) |
| "Forty one patients with hairy cell leukemia (HCL) were treated with 2-chloro-deoxyadenosine (2-CdA) administered in various schedules." | ( Błasińska-Morawiec, M; Dwilewicz-Trojaczek, J; Grieb, P; Hansz, J; Hellmann, A; Hołowiecki, J; Kazimierczak, M; Komarnicki, M; Konopka, L; Kotlarek-Haus, S; Krawczyk-Kulis, M; Krykowski, E; Kuratowska, Z; Maj, S; Robak, T; Urasiński, L; Usnarska-Zubkiewicz, L; Zaucha, JM; Zdziarska, B, 1996) |
| "The long-term outcome of patients with hairy cell leukemia resistant to interferon-alpha (IFN-alpha) following treatment with deoxycoformycin (DCF) was examined, and the kinetics of recovery of lymphocyte subsets and factors influencing the rate of recovery investigated." | ( Kurzrock, R; Seymour, JF; Talpaz, M, 1997) |
| "The discovery of effective therapy for hairy cell leukemia (HCL) has increased the relevance of long-term outcome." | ( Adams, T; Estey, E; Jiang, H; Keating, MJ; Kurzrock, R; O'Brien, S; Strom, SS; Talpaz, M, 1997) |
| "We treated 19 patients with hairy cell leukemia (HCL) with 2-chlorodeoxyadenosine." | ( Chrobák, L; Dĕdic, K; Dulícek, P; Foglová, J; Maisnar, V; Plísková, L; Podzimek, K; Zák, P, 1997) |
| "Two patients with hairy cell leukemia (HCL) who had relapsed after splenectomy and alpha-interferon therapy were treated with 2-chlorodeoxyadenosine (2-CdA) for 7 days." | ( Haanen, C; Idink-Mecking, CA; Reutelingsperger, C; Richel, DJ; Schaafsma, MR; Vermes, I, 1998) |
| "We treated 49 patients with active hairy cell leukemia with continuous infusion of cladribine at a dose of 0." | ( Rai, KR, 1998) |
| "A total of 358 patients with hairy cell leukemia were treated with cladribine at 0." | ( Burian, C; Koziol, JA; Piro, LD; Saven, A, 1998) |
| "Active hairy cell leukemia is associated with an increase of RDW (Red Cell Distribution Width) which normalizes after successful therapy with 2-chlorodeoxyadenosine (2-CdA)." | ( Chrobák, L; Dedic, K; Plísková, L; Podzimek, K; Zák, P, 1998) |
| "Cladribine treatment of hairy cell leukemia (HCL) is complicated by neutropenic fever in 42% of patients despite documented infections being relatively uncommon." | ( Adusumalli, J; Burian, C; Koziol, JA; Saven, A, 1999) |
| "A 49-year-old man diagnosed with hairy cell leukemia (HCL) achieved a complete remission lasting 4 years after treatment with cladrabine and subsequently developed acute myeloid leukemia." | ( Al-Fiar, F; Curtis, J; Lipton, JH; Meharchand, J, 1999) |
| "We report on 14 patients with hairy cell leukemia who were treated with 2-CdA at our department between 1993 and 1997." | ( Chott, A; Füreder, W; Geissler, K; Gisslinger, H; Jäger, U; Lechner, K; Valent, P; Weltermann, A, 1999) |
| "A 36-year-old man with treated hairy cell leukemia developed a skin infection due to Mycobacterium marinum." | ( Lanternier, G; Le Vagueresse, R; Saint-Blancard, P; Samson, T; Schmoor, P; Soler, C, 2000) |
| "The leukemic cells of a patient with hairy cell leukemia were treated in vitro with 2'-deoxycoformycin (dCF), an inhibitor of adenosine deaminase, and deoxyadenosine (dAdo)." | ( Maruyama, Y; Nakamura, N; Ogawa, K; Shichishima, T, 2000) |
| "In patients with hairy cell leukemia (HCL) who received chemotherapeutic treatment and achieved complete remission (CR), minimal residual disease (MRD) can be detected in bone marrow biopsies using immunohistochemical (IHC) techniques." | ( Bengio, R; Narbaitz, M; Palacios, F; Sarmiento, M; Scolnik, M, 2000) |
| "Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA) induces in 85% patients complete remission." | ( Chrobák, L; Dĕdic, K; Podzimek, K; Zák, P, 2000) |
| "The standard therapy for hairy cell leukemia (HCL) is with the nucleoside analogs, 2"-deoxycoformycin (dCF) or 2-chlorodeoxyadenosine (CdA), which produce morphologic complete remissions (CRs) in the majority of patients, although residual hairy cells can frequently be detected by molecular or immunologic techniques." | ( Johnston, JB; Savoie, L, 2001) |
| "The treatment of choice for hairy cell leukemia (HCL) are the purine analogs pentostatin and cladribine." | ( Hensel, M; Ho, AD, 2003) |
| "Although remission of hairy cell leukemia (HCL) after treatment with 2-chlorodeoxyadenosine (2-CdA) appears to be long lasting, few reports currently provide results from follow-up exceeding 5 years." | ( Alinari, L; Baccarani, M; Gabriele, A; Marchi, E; Musuraca, G; Pileri, S; Stefoni, V; Tani, M; Zinzani, PL, 2004) |
| "The overall survival of patients with hairy cell leukemia (HCL) has significantly increased in recent years because of the development of effective treatments such as interferon alpha and purine analogs." | ( Gupta, M; Hassan, R; Kern, W; Ozer, H, 2004) |
| "Secondary malignancies in patients with hairy cell leukemia (HCL) are well described and treatment of HCL is discussed as their cause." | ( Gratwohl, A; Rimner, T; Tichelli, A; Went, P, 2006) |
| "Both hairy cell leukemia and antiphospholipid syndrome responded to lymphocytotoxic treatment with 2-chloro-deoxyadenosine." | ( Dincol, G; Diz-Kucukkaya, R; Inanc, M; Kamali, S; Kural, F, 2007) |
| "The current hairy cell leukemia (HCL) treatment is excellent, but evidence of cure with purine analogs cladribine and pentostatin, is lacking." | ( Fitzgerald, DJ; Kreitman, RJ; Pastan, I, 2009) |
| "We present a case of a patient with hairy cell leukemia and pulmonary aspergillosis who developed a cycotic pulmonary artery aneurysm despite prolonged antifungal therapy." | ( Erasmus, J; Mattiuzzi, GN; Sever, M; Verstovsek, S, 2010) |
| "Treatment of hairy cell leukemia (HCL), a disease first described in 1958, has evolved from splenectomy, which resulted in a normalization of blood counts in about 41% of patients and an improvement in the remaining 59% of patients but with a time to failure of only approximately 19 months, through treatment in the early 1980s with interferon, which resulted in the same high overall response rate but with a time to failure of approximately 31 months." | ( Golomb, HM, 2011) |
| "Treatment of hairy cell leukemia (HCL) with cladribine induces durable remissions." | ( Ben-Yehuda, D; Ganzel, C; Gatt, ME; Goldschmidt, N; Maly, A, 2012) |
| "Twenty-nine consecutive patients with hairy cell leukemia (HCL) were treated in two institutions with interferon (IFN, n = 18) or cladribine (n = 11), between July 1987 and May 2011." | ( Alarcón-Urdaneta, C; Calderón-García, J; Gómez-Almaguer, D; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Tarín-Arzaga, LC, 2012) |
| "We report a patient with hairy cell leukemia in complete remission who, after a single cycle of chemotherapy with cladribine, presented fever and neurological deficits." | ( Annibali, O; Avvisati, G; Bianchi, A; Cerchiara, E; Cirillo, M; Gherardi, G; Girardi, K; Marchesi, F; Miglio, C; Onetti Muda, A; Paviglianiti, A; Tirindelli, M; Tomarchio, V, 2012) |
| "Describe hairy cell leukemia (HCL) treatment patterns using a large, nationally representative US database." | ( DeKoven, M; Divino, V; Gao, G; Gaughan, A; Karve, S; Knopf, KB; Lanasa, MC, 2017) |
| "Treatment of hairy cell leukemia (HCL) with alfa-interferon and purine analogs significantly prolongs survival in these patients." | ( Bogdanovic, A; Colovic, N; Gotic, M; Kraguljac-Kurtovic, N; Marisavljevic, D, 2019) |
| "The treatment of hairy cell leukemia (HCL) has considerably changed over years." | ( Argnani, L; Broccoli, A; Carella, M; Casadei, B; Coppola, PE; Gabrielli, G; Lolli, G; Morigi, A; Nanni, L; Pellegrini, C; Sabattini, E; Stefoni, V; Terragna, C; Zinzani, PL, 2021) |
| "Frontline treatment of hairy cell leukemia (HCL) with a single course of the purine nucleoside analog (PNA) produces a high rate of complete remission (CR) with prolonged durations." | ( Brander, D; Gonter-Aubin, K; Hanlon, A; Hill, BT; Hu, R; Kabel, C; Khajavian, S; Madanat, Y; Mato, A; Mian, A; Park, JH; Pinilla-Ibarz, J; Shadman, M; Stephens, DM; Tallman, M; Wei, W, 2022) |
| "In classical hairy cell leukemia (HCL), standard treatments including purine analogs achieve a durable response (up to 90%), but lead to severe immunosuppression and long-lasting depletion of CD4 + T lymphocytes." | ( Balabanov, S; Konrat, J; Manz, MG; Meier-Abt, F; Roiss, M; Rösler, W; Widmer, CC; Zenz, T, 2023) |
| "In classical hairy cell leukemia (HCL), standard treatments including purine analogs achieve a durable response (up to 90%), but lead to severe immunosuppression and long-lasting depletion of CD4 + T lymphocytes." | ( Balabanov, S; Konrat, J; Manz, MG; Meier-Abt, F; Roiss, M; Rösler, W; Widmer, CC; Zenz, T, 2023) |